Abstract |
The efficacy and safety of tositumomab/ iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse large B-cell lymphoma patients who responded to first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Fifteen patients (median age, 52 years) received dosimetric and therapeutic doses of TST/I-131 TST. The most common Grade 3/4 hematologic adverse events were decreased absolute neutrophil count (47%), white blood cell count (40%), platelet count (27%), and hemoglobin (20%). The complete response (CR) rate increased from 60% post-CHOP to 80% post TST / I-131 TST. With a median follow-up of 120.0 months (range, 14-130 months), median duration of response (95% confidence intervals) was 58.4 months (12.0-not reached [NR]) for patients with confirmed complete response and 58.4 months (20.9-NR) for all confirmed responders. Median progression-free survival and time to treatment failure were 63.0 months (16.1-NR). Median overall survival was not reached; 2 patients died on study. CHOP and TST/I-131 TST demonstrated clinical activity with acceptable toxicity.
|
Authors | John P Leonard, Stephanie A Gregory, Hedy Smith, Thierry J Horner, Vanessa C Williams, Patricia Giampietro, Thomas S Lin |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 16
Issue 4
Pg. 191-6
(Apr 2016)
ISSN: 2152-2669 [Electronic] United States |
PMID | 26832194
(Publication Type: Journal Article)
|
Copyright | Copyright © 2016 Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- Vincristine
- Doxorubicin
- Cyclophosphamide
- tositumomab I-131
- Prednisone
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cyclophosphamide
(therapeutic use)
- Disease-Free Survival
- Doxorubicin
(therapeutic use)
- Female
- Humans
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, pathology)
- Male
- Middle Aged
- Prednisone
(therapeutic use)
- Treatment Outcome
- Vincristine
(therapeutic use)
- Young Adult
|